What concerns about the early use of CAR T therapy were addressed in the ODAC hearing?

In this week's #AskDrDurie, myeloma expert Dr. Brian G.M. Durie answers the question: What concerns about the early use of CAR T-cell therapy were addressed in the ODAC hearing? _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.

Advancements in Myeloma | What progress towards a cure and prevention has been made?
▶︎

Advancements in Myeloma | What progress towards a cure and prevention has been made?

Updated Version Available - All About CARVYKTI #myeloma
▶︎

Updated Version Available - All About CARVYKTI #myeloma

Challenges with the real-world use of CAR-T therapy in multiple myeloma
▶︎

Challenges with the real-world use of CAR-T therapy in multiple myeloma

These Two Drugs Eliminated Cancer Metastasis | Here's What You Need to Know
▶︎

These Two Drugs Eliminated Cancer Metastasis | Here's What You Need to Know

Legend Biotech sets up CAR-T therapy production in Flanders
▶︎

Legend Biotech sets up CAR-T therapy production in Flanders

Recent Advances in Multiple Myeloma with Dr. Dan Vogl
▶︎

Recent Advances in Multiple Myeloma with Dr. Dan Vogl

Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PHD | ASH 2022
▶︎

Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PHD | ASH 2022

My Cancer Diagnosis Came Out of Nowhere! - Tim | Multiple Myeloma | The Patient Story
▶︎

My Cancer Diagnosis Came Out of Nowhere! - Tim | Multiple Myeloma | The Patient Story

How long will I live with multiple myeloma, and is there a cure? #myeloma
▶︎

How long will I live with multiple myeloma, and is there a cure? #myeloma

"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!
▶︎

"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!

CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma
▶︎

CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma

CAR T-cell Therapy Two Years Later: Nick's Story - Nebraska Medicine
▶︎

CAR T-cell Therapy Two Years Later: Nick's Story - Nebraska Medicine

028 Myeloma in 2026 - What's Coming Next and Why It Matters
▶︎

028 Myeloma in 2026 - What's Coming Next and Why It Matters

This New Histamine Treatment Helped 89% of Patients
▶︎

This New Histamine Treatment Helped 89% of Patients

Neurologist Warns: If Your NAILS Look Like THIS After 60 Your Body May be Hiding 4 Diseases| Mandell
▶︎

Neurologist Warns: If Your NAILS Look Like THIS After 60 Your Body May be Hiding 4 Diseases| Mandell

I Beat Stage 4 Cancer in 75 Days! Incredible/Emotional Vlog Update
▶︎

I Beat Stage 4 Cancer in 75 Days! Incredible/Emotional Vlog Update

Is there a cure for AML? #AML
▶︎

Is there a cure for AML? #AML

Could CAR-T Therapy Be an Option for You? Eligibility Criteria Explained
▶︎

Could CAR-T Therapy Be an Option for You? Eligibility Criteria Explained

CAR T-Cell Therapies | High Impact Topic (HIT)
▶︎

CAR T-Cell Therapies | High Impact Topic (HIT)

Expanding Myeloma Treatments: Power of Bispecific & Trispecific Antibodies| Dr. Aravind Ramakrishnan
▶︎

Expanding Myeloma Treatments: Power of Bispecific & Trispecific Antibodies| Dr. Aravind Ramakrishnan